Welcome to our dedicated page for Quanterix Corporation news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix Corporation stock.
Quanterix Corporation (NASDAQ: QTRX) is a pioneering life sciences company renowned for its groundbreaking ultra-sensitive diagnostic platform. This innovative technology measures individual proteins at concentrations that are up to 1000 times lower than the best immunoassays available today.
At the core of Quanterix's offerings is the Single Molecule Array (Simoa™) technology, which enables the detection and quantification of biomarkers that were previously difficult or impossible to measure. This advancement opens up new applications in various fields, including life sciences research, in-vitro diagnostics, companion diagnostics, and blood screening.
Founded by the esteemed scientist Dr. David Walt, who also co-founded Illumina, Quanterix benefits from a robust intellectual property portfolio initially developed at Tufts University. The company is venture capital-backed and has exclusive licensing rights to this broad IP portfolio.
Quanterix's product lineup is diverse and includes:
- Simoa platform
- Assay Kits
- LDTs & Assay Services
- Simoa p-Tau 217
- Simoa NfL LDT
- Simoa p-Tau 181 LDT
- HD-X Automated Immunoassay Analyzer
- SR-X Biomarker Detection System
- SP-X Imaging and Analysis System
- Simoa Accelerator Laboratory
- Homebrew - Custom Assay Development
- Uman NF-Light
The Simoa bead-based and planar array platforms are designed to detect protein biomarkers in low concentrations in blood, serum, and other fluids, which are undetectable using conventional analog immunoassay technologies.
Quanterix continues to push the boundaries of precision health for life sciences research and diagnostics, tackling significant unmet needs and contributing meaningfully to the scientific community.
Quanterix Corporation (NASDAQ: QTRX) will host a conference call on August 8, 2022, at 4:30 PM ET to discuss its Q2 2022 financial results. The company will release its earnings report prior to the call, accessible on its website. This call will be led by President and CEO Masoud Toloue and CFO Michael Doyle. Quanterix focuses on ultrasensitive biomarker detection to advance precision health, impacting various therapeutic areas like oncology and neurology. More information is available at www.quanterix.com.
Quanterix Corporation (NASDAQ: QTRX) announced the validation of its laboratory developed test (LDT) for measuring phospho-Tau 181 (pTau-181) in plasma, aiding Alzheimer's disease diagnosis. This is the first pTau-181 plasma test for clinical use in the U.S., focusing on adults with cognitive impairment. The test enhances diagnostic sensitivity and specificity alongside existing markers like amyloid beta. Results will be presented at the Alzheimer’s Association International Conference in San Diego from July 31 to August 4. The LDT will be offered through Quanterix’s Accelerator Laboratory.
Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at 8:40 a.m. EST. Attendees can register for the live webcast here. Toloue will also conduct one-on-one meetings with institutional investors on the same day. Replays will be available for 90 days on Quanterix's investor relations website. Quanterix focuses on digitizing biomarker analysis to enhance precision health.
Quanterix Corporation (NASDAQ: QTRX) has appointed Karen A. Flynn, Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), to its Board of Directors effective June 6, 2022. With over 35 years in the pharmaceutical services industry, Flynn's experience includes leadership roles at Catalent and West Pharmaceutical Services. Her expertise in commercial strategy and operations is expected to drive Quanterix's growth and enhance its impact in healthcare research and diagnostics.
Quanterix (NASDAQ: QTRX) announced a 9% year-over-year revenue growth for Q1 2022, totaling
Quanterix Corporation (NASDAQ: QTRX) will release its Q1 2022 financial results on May 10, 2022, before trading begins. The management team, including President & CEO Masoud Toloue and CFO Michael Doyle, will discuss the results in a conference call at 8:30 a.m. EST. Interested listeners can join the call via phone or a live webcast. Quanterix specializes in digitizing biomarker analysis to enhance precision health through its Simoa technology, supporting research across various therapeutic areas.
Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® neurofilament light chain (NfL) plasma test received FDA Breakthrough Device designation for assessing disease activity in relapsing-remitting multiple sclerosis (RRMS) patients. This designation supports accelerated development and regulatory review for technologies that address significant medical needs. The NfL test quantitatively measures NfL in blood, aiding in identifying RRMS patients' relapse risks. This marks the second Breakthrough Device designation for Quanterix, following the phospho-Tau 181 test for Alzheimer’s disease.
Quanterix Corporation (NASDAQ: QTRX) has announced a significant advancement in multiple sclerosis (MS) management through its Simoa® technology. A comprehensive study published in The Lancet Neurology established reference ranges for the serum neurofilament light chain (sNfL) biomarker, aiding in disease assessment at the individual level. The study analyzed over 20,000 samples, creating a robust database for clinical interpretation. This development hopes to enhance personalized treatment decisions for MS patients.
Quanterix Corporation (NASDAQ: QTRX) has partnered with the Alzheimer’s Drug Discovery Foundation (ADDF) to enhance the development of a multi-analyte plasma test for early Alzheimer's disease detection. Funded clinical trials will be conducted in collaboration with Amsterdam University Medical Centers, led by Professor Charlotte Teunissen. The initiative aims to provide accessible diagnostics to link patients with new therapies. The ADDF has financed over $209 million for Alzheimer's drug development since its inception.
FAQ
What is the current stock price of Quanterix Corporation (QTRX)?
What is the market cap of Quanterix Corporation (QTRX)?
What is the core technology of Quanterix Corporation?
What are some applications of Quanterix's technology?
Who founded Quanterix Corporation?
What product platforms does Quanterix offer?
What makes Quanterix's diagnostic platform unique?
Is Quanterix publicly traded?
What significant achievements has Quanterix made recently?
What fluids can Quanterix's platforms detect biomarkers in?
Does Quanterix offer custom assay development?